Search details
1.
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
Int J Cancer
; 153(6): 1241-1250, 2023 09 15.
Article
in English
| MEDLINE | ID: mdl-37294085
2.
Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.
Curr Treat Options Oncol
; 22(8): 73, 2021 06 29.
Article
in English
| MEDLINE | ID: mdl-34185197
3.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
J Clin Oncol
; 42(11): 1222-1228, 2024 Apr 10.
Article
in English
| MEDLINE | ID: mdl-38227898
4.
SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022).
Clin Transl Oncol
; 25(9): 2692-2706, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37204633
5.
Intermediate molecular phenotypes to identify genetic markers of anthracycline-induced cardiotoxicity risk.
bioRxiv
; 2023 Jan 06.
Article
in English
| MEDLINE | ID: mdl-36712139
Results
1 -
5
de 5
1
Next >
>>